The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation
Abstract
Background—: Recent studies have investigated alternatives to warfarin for stroke prophylaxis in patients with atrial fibrillation (AF), but whether these alternatives are cost-effective is unknown. Methods and Results—: On the basis of the results from Randomized Evaluation of Long Term Anticoagulation Therapy (RE-LY) and other trials, we developed a decision-analysis model to compare the cost and quality-adjusted survival of various antithrombotic therapies. We ran our Markov model in a hypothetical cohort of 70-year-old patients with AF using a cost-effectiveness threshold of $50 000/quality-adjusted life-year. We estimated the cost of dabigatran as US $9 a day. For a patient with an average risk of major hemorrhage (≈3%/y), the most cost-effective therapy depended on stroke risk. For patients with the lowest stroke rate (CHADS 2 stroke score of 0), only aspirin was cost-effective. For patients with a moderate stroke rate (CHADS 2 score of 1 or 2), warfarin was cost-effective unless the risk of hemorrhage was high or quality of international normalized ratio control was poor (time in the therapeutic range <57.1%). For patients with a high stroke risk (CHADS 2 stroke score ≥3), dabigatran 150 mg (twice daily) was cost-effective unless international normalized ratio control was excellent (time in the therapeutic range >72.6%). Neither dabigatran 110 mg nor dual therapy (aspirin and clopidogrel) was cost-effective. Conclusions—: Dabigatran 150 mg (twice daily) was cost-effective in AF populations at high risk of hemorrhage or high risk of stroke unless international normalized ratio control with warfarin was excellent. Warfarin was cost-effective in moderate-risk AF populations unless international normalized ratio control was poor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
Self-citationHart, R. G., Pearce, L. A., & Aguilar, M. I. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-12-200706190-00007 · Cited by 4,793
Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
Bhatt, D. L., Fox, K. A. A., Hacke, W., Berger, P. B., Black, H. R., Boden, W. E., Cacoub, P., Cohen, E. A., Creager, M. A., Easton, J. D., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060989 · Cited by 2,837
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Recommendations of the Panel on Cost-Effectiveness in Health and Medicine
Weinstein, M. C. (1996) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1996.03540150055031 · Cited by 2,455
Markov Models in Medical Decision Making: A Practical Guide
Sonnenberg, F. A., & Beck, J. R. (1993) · Medical Decision Making · doi:10.1177/0272989x9301300409 · Cited by 2,419
Pharmacology and Management of the Vitamin K Antagonists
Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M., & Palareti, G. (2008) · Chest · doi:10.1378/chest.08-0670 · Cited by 2,118
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
(1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420130036007 · Cited by 2,071
EAFT (European Atrial Fibrillation Trial) Study Group (1993) · The Lancet · doi:10.1016/0140-6736(93)92358-z · Cited by 1,741
Mant, J., Hobbs, F. R., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., & Murray, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61233-1 · Cited by 1,556
Palareti, G., Leali, N., Coccheri, S., Poggi, M., Manotti, C., D'Angelo, A., Pengo, V., Erba, N., Moia, M., Ciavarella, N., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01109-9 · Cited by 1,333
Effect of Intensity of Oral Anticoagulation on Stroke Severity and Mortality in Atrial Fibrillation
Hylek, E. M., Go, A. S., Chang, Y., Jensvold, N. G., Henault, L. E., Selby, J. V., & Singer, D. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022913 · Cited by 1,277
Eriksson, B. I., Dahl, O. E., Rosencher, N., Kurth, A. A., van Dijk, C. N., Frostick, S. P., Prins, M. H., Hettiarachchi, R., Hantel, S., Schnee, J., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61445-7 · Cited by 1,116
Wallentin, L., Yusuf, S., Ezekowitz, M. D., Alings, M., Flather, M., Franzosi, M. G., Pais, P., Dans, A., Eikelboom, J., Oldgren, J., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61194-4 · Cited by 1,013
Gage, B. F., Yan, Y., Milligan, P. E., Waterman, A. D., Culverhouse, R., Rich, M. W., & Radford, M. J. (2006) · American Heart Journal · doi:10.1016/j.ahj.2005.04.017 · Cited by 1,008
Self-citationDries, D., Exner, D., Gersh, B., Domanski, M., Waclawiw, M., & Stevenson, L. (1998) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(98)00297-6 · Cited by 964
Atrial fibrillation management: a prospective survey in ESC Member Countries
Nieuwlaat, R., Capucci, A., Camm, A. J., Olsson, S. B., Andresen, D., Davies, D. W., Cobbe, S., Breithardt, G., Le Heuzey, J.-Y., Prins, M. H., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi505 · Cited by 829
Gage, B. F., van Walraven, C., Pearce, L., Hart, R. G., Koudstaal, P. J., Boode, B. S. P., & Petersen, P. (2004) · Circulation · doi:10.1161/01.cir.0000145172.55640.93 · Cited by 749
Self-citationThe Beaver Dam Health Outcomes study: Initial Catalog of Health-state Quality Factors
Fryback, D. G., Dasbach, E. J., Klein, R., Klein, B. E. K., Dorn, N., Peterson, K., & Martin, P. A. (1993) · Medical Decision Making · doi:10.1177/0272989x9301300202 · Cited by 733
van Walraven, C., Hart, R. G., Singer, D. E., Laupacis, A., Connolly, S., Petersen, P., Koudstaal, P. J., Chang, Y., & Hellemons, B. (2002) · JAMA · doi:10.1001/jama.288.19.2441 · Cited by 714
The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J., & Roth, W. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019083 · Cited by 689
STROKEPREVENTIONINATRIALFIBRIL (1994) · The Lancet · doi:10.1016/s0140-6736(94)91577-6 · Cited by 621
Why Do Patients With Atrial Fibrillation Not Receive Warfarin?
Bungard, T. J., Ghali, W. A., Teo, K. K., McAlister, F. A., & Tsuyuki, R. T. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.1.41 · Cited by 593
Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project.
Dennis, M. S., Burn, J. P., Sandercock, P. A., Bamford, J. M., Wade, D. T., & Warlow, C. P. (1993) · Stroke · doi:10.1161/01.str.24.6.796 · Cited by 567
The Risk for and Severity of Bleeding Complications in Elderly Patients Treated with Warfarin
Fihn, S. D., Callahan, C. M., Martin, D. C., McDonell, M. B., Henikoff, J. G., White, R. H., & National Consortium of Anticoagulation Clinics* (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-11-199606010-00004 · Cited by 555
Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation
Freeman, J. V., Zhu, R. P., Owens, D. K., Garber, A. M., Hutton, D. W., Go, A. S., Wang, P. J., & Turakhia, M. P. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-154-1-201101040-00289 · Cited by 429
The Effect of Stroke and Stroke Prophylaxis With Aspirin or Warfarin on Quality of Life
Gage, B. F. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.16.1829 · Cited by 370
Self-citationEckman, M. H., Rosand, J., Greenberg, S. M., & Gage, B. F. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-2-200901200-00005 · Cited by 283
Self-citationGitter, M. J., Jaeger, T. M., Petterson, T. M., Gersh, B. J., & Silverstein, M. D. (1995) · Mayo Clinic Proceedings · doi:10.4065/70.8.725 · Cited by 276
Hellemons, B. S. P., Langenberg, M., Lodder, J., Vermeer, F., Schouten, H. J. A., Lemmens, T., van Ree, J. W., & Knottnerus, J. A. (1999) · BMJ · doi:10.1136/bmj.319.7215.958 · Cited by 226
Contrast sonography for detection of vesicoureteral reflux
Kaneko, K., Kuwatsuru, R., Fukuda, Y., Yamataka, A., Yabuta, K., Katayama, H., & Miyano, T. (1994) · The Lancet · doi:10.1016/s0140-6736(94)92123-7 · Cited by 222
Thomson, R., Parkin, D., Eccles, M., Sudlow, M., & Robinson, A. (2000) · The Lancet · doi:10.1016/s0140-6736(00)90012-6 · Cited by 179
LAUNBJERG, J., EGEBLAD, H., HEAF, J., NIELSEN, N. H., FUGLEHOLM, A. M., & LADEFOGED, K. (1991) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1991.tb00358.x · Cited by 169
Costs and Effectiveness of Ximelagatran for Stroke Prophylaxis in Chronic Atrial Fibrillation
O’Brien, C. L. (2005) · JAMA · doi:10.1001/jama.293.6.699 · Cited by 153
Inpatient costs of specific cerebrovascular events at five academic medical centers.
Holloway, R. G., Witter, D. M., Lawton, K. B., Lipscomb, J., & Samsa, G. P. (1996) · PubMed · Cited by 150
Farrell, B., Kenyon, S. L., & Shakur‐Still, H. (2010) · Trials · doi:10.1186/1745-6215-11-78 · Cited by 145
Survival after stroke — The impact of CHADS2 score and atrial fibrillation
Henriksson, K. M., Farahmand, B. Y., Johansson, S., Åsberg, S., Terént, A., & Edvardsson, N. G. (2009) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.11.122 · Cited by 135
Leibson, C. L., Hu, T., Brown, R. D., Hass, S., O’Fallon, W. M., & Whisnant, J. P. (1996) · PubMed · Cited by 109
Infant mortality statistics from the 1999 period linked birth/infant death data set.
Mathews, T. J., MacDorman, M. F., & Menacker, F. (2002) · PubMed · Cited by 101
Boulanger, L., Kim, J. S., Friedman, M., Hauch, O., Foster, T., & Menzin, J. (2006) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2006.00790.x · Cited by 94
Atrial Fibrillation: A Risk Factor for Increased Mortality – An AVID Registry Analysis
Wyse, D. G., Love, J. C., Yao, Q., Carlson, M. D., Cassidy, P., Greene, L., Martins, J. B., Ocampo, C. M., Raitt, M. H., Schron, E. P., et al. (2001) · Journal of Interventional Cardiac Electrophysiology · doi:10.1023/a:1011460631369 · Cited by 62
Wehinger, C., Stöllberger, C., Länger, T., Schneider, B., & Finsterer, J. (2001) · Stroke · doi:10.1161/hs1001.097090 · Cited by 58
Yuan, Z., Bowlin, S. J., Einstadter, D., Cebul, R. D., Conners, A. R., & Rimm, A. A. (1998) · American Journal of Public Health · doi:10.2105/ajph.88.3.395 · Cited by 48
Hu, D., Zhang, H.-P., Sun, Y., & Jiang, L. (2006) · PubMed · Cited by 47
Atrial fibrillation in mainland China: epidemiology and current management
Zhang, S. (2009) · Heart · doi:10.1136/hrt.2008.146589 · Cited by 37
Vemmos, K. N., Tsivgoulis, G. K., Spengos, K. M., Manios, E. D., Xinos, K., Vassilopoulou, S., Zakopoulos, N., & Moulopoulos, S. D. (2005) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2005.08.005 · Cited by 29
Hart, R. G., Bhatt, D. L., Hacke, W., Fox, K. A. A., Hankey, G. J., Berger, P. B., Hu, T., & Topol, E. J. (2008) · Cerebrovascular Diseases · doi:10.1159/000118380 · Cited by 28
Cost Effectiveness of Enoxaparin in Acute ST-Segment Elevation Myocardial Infarction
Marcoff, L., Zhang, Z., Zhang, W., Ewen, E. F., Jurkovitz, C. T., Leguet, P., Kolm, P., & Weintraub, W. S. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.05.060 · Cited by 9
Cited by
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,822
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors/Task Force Members, Camm, A. J., Lip, G. Y. H., De Caterina, R., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P., ESC Committee for Practice Guidelines (CPG), et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs253 · Cited by 2,899
Meschia, J. F., Bushnell, C., Boden-Albala, B., Braun, L. T., Bravata, D. M., Chaturvedi, S., Creager, M. A., Eckel, R. H., Elkind, M. S. V., Fornage, M., et al. (2014) · Stroke · doi:10.1161/str.0000000000000046 · Cited by 2,650
Kamel, H., & Healey, J. S. (2017) · Circulation Research · doi:10.1161/circresaha.116.308407 · Cited by 417
Singer, D. E., Chang, Y., Borowsky, L. H., Fang, M. C., Pomernacki, N. K., Udaltsova, N., Reynolds, K., & Go, A. S. (2013) · Journal of the American Heart Association · doi:10.1161/jaha.113.000250 · Cited by 405
Metadata
- Authors
- Shah, S. V., & Gage, B. F.
- Venue
- Circulation
- Published
- 2011-06-07
- Volume
- 123
- Issue
- 22
- Pages
- 2562-2570
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W1993614294
- Cited by
- 337
- References
- 54
- FWCI
- 47.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.